Reference intervals: thyroid-stimulating hormone 0.3 to 4.2 mU/L; creatine kinase 55 to 117 U/L; high-density lipoprotein cholesterol 0.90 to 2.20 mmol/L; triglycerides 0.45 to 2.20 mmol/L; low-density lipoprotein cholesterol 2.00 to 3.40 mmol/L; and serum creatinine 70 to 133 μmol/L.
| DATE | TOTAL CHOLESTEROL (MMOL/L) | HIGH-DENSITY LIPOPROTEIN CHOLESTEROL ( MMOL /L) | LOW-DENSITY LIPOPROTE IN CHOLESTEROL ( MMOL /L) | TRIGLYCERIDES (MMOL/L) | TOTAL CHOLESTEROL/ HIGH-DENSITY LIPOPROTEIN CHOLESTEROL | CREATINE KINASE (U/L) | THYROID- STIMULATING HORMONE (MU/L) | SERUM CREATININE (μMOL/L) | MEDICATIONS |
|---|---|---|---|---|---|---|---|---|---|
| November 2003 | 10.80 | 1.50 | 8.50 | 1.66 | 7.2 | NM | NM | NM | Rosuvastatin 10 mg/d initiated |
| February 2004 | 6.01 | 1.30 | 3.70 | 2.15 | 4.6 | NM | NM | NM | Rosuvastatin 10 mg/d |
| June 2004 | 4.20 | 1.40 | 2.10 | 1.46 | 3.0 | 4517 | NM | 135 | Rosuvastatin stopped; ezetimibe 10 mg/d initiated |
| July 2004 | 6.99 | 1.09 | 4.69 | 2.68 | 6.4 | 3120 | NM | 136 | Ezetimibe 10 mg/d |
| August 2004 | 7.41 | 1.09 | NM | 4.68 | 6.7 | 1446 | 114.60 | 140 | Ezetimibe 10 mg/d; levothyroxine 0.1 mg/d initiated |
| November 2004 | 5.21 | 1.01 | 3.50 | 1.53 | 5.2 | 153 | 4.80 | NM | Levothyroxine 0.1 mg/d; ezetimibe 10 mg/d; pravastatin 20 mg/d initiated* |
| February 2005 | 5.70 | 1.09 | 3.29 | 2.75 | 5.2 | 143 | 5.40 | NM | Ezetimibe 10 mg/d; levothyroxine 0.15 mg/d |
| December 2005 | 6.10 | 1.40 | 3.70 | 2.22 | 4.4 | 327 | NM | NM | Fluvastatin 20 mg/d started; levothyroxine 0.15 mg/d; niacin ER 500 mg/d initiated; ezetimibe 10 mg/d |
| January 2006 | 4.20 | 1.30 | 1.30 | 1.12 | 3.2 | 163 | 1.99 | NM | Fluvastatin 20 mg/d; ezetimibe 10 mg/d; niacin ER 500 mg/d; levothyroxine 0.15 mg/d |
NM = not measured.
↵* Discontinued by patient shortly after prescription because myalgia recurred.